Thieler Law Corp advises investors with losses exceeding $100,000 of the March 29, 2019 lead plaintiff deadline in a class action lawsuit filed against Tyme Technologies Inc (NASDAQ: TYME) (“Tyme” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of New York and investors, who purchased Tyme Technologies Inc securities between March 14, 2018 and January 18, 2019, have until March 29, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Tyme Technologies Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and as a result, Tyme's public statements were materially false and misleading at all relevant times.

On January 18, 2019, the Company revealed the results from the Phase II Study. Although Tyme characterized the results as positive, stating that SM-88 "improves survival," the trial did not include a control group, and Tyme's announcement merely compared survival data to historical controls. Market commentators were quick to highlight this glaring deficiency in the Phase II Study.

Following this news, NASDAQ: TYME fell from $3.73 per share on January 17, 2019 to $2.41 per share on January 18, 2018.

If you were negatively impacted by your investment in Tyme Technologies Inc securities between March 14, 2018 and January 18, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185